Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection

AIDS

Volumn 20, Issue 6, 2006, Pages 837-845

  Powers, April E ^a,e   Marden, Susan F ^a   McConnell, Rose ^a   Leidy, Nancy K ^b   Campbell, Colleen M ^a   Soeken, Karen L ^c   Barker, Chris ^d   Davey, Richard T ^e   Dybul, Mark R ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d SCIOS INC   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISTRESS SYNDROME; DRUG INTERMITTENT THERAPY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM DISTRESS SCALE; SYMPTOMATOLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS INDICATORS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 33646712149     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000218547.39339.13     Document Type: Article

References (69)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
3. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-626.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
5. Panel on Clinical Practices for Treatment of HIV Infection, Department Health and Human Services. Guidelines for the use of anitretorviral agents in HIV-1-infected adults and adolescents. Available at www.AIDSinfo.nih.gov; Accessed November 4, 2005.
6. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S112-S117.
7. Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S118-S122.
8. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
9. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-361.
10. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109-2117.
11. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003; 139:810-816.
12. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005; 17:10-22.
13. Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, et al. Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res 2000; 9:977-985.
14. Wu AW, Ammassari A, Antinori A. Adherence to antiretroviral therapy: where are we, and where do we go from here? J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S95-S97.
15. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S98-S102.
16. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-449.
17. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S123-S127.
18. Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 (suppl. 3):S128-S131.
19. Stone VE, Clarke J, Lovell J, Steger KA, Hirschhorn LR, Boswell S, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998; 13:586-593.
20. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002; 46:93-108.
21. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19:124-133.
22. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001; 98:15161-15166.
23. Lori F, Foli A, Lisziewicz J. Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. J Antimicrob Chemother 2002; 50:155-160.
24. Dybul M. Structured treatment interruption: approaches and risks. Curr Infect Dis Rep 2002; 4:175-180.
25. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-396.
26. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600.
27. Montaner J, Harris M, Hogg R. Structured treatment interruptions: a risky business. Clin Infect Dis 2005; 40:601-603.
28. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-1226.
29. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
30. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397-403.
31. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F29-F40.
32. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:e64.
33. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic III) 2002; 1:95-103.
34. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-899.
35. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-1443.
36. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-415.
37. Pai N, Tulsky J, Lawrence J, Colford J Jr, Reingold A. Strucured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005. 4:CD005482.
38. Tuldra A, Fumaz CR, Ferrer MJ, Paredes R, Romeu J, Ruiz L, et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS 2001; 15:1904-1906.
39. Krentz HB, Gill MJ. The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. AIDS 2003; 17:631-633.
40. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998; 12:1495-1502.
41. Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antivir Ther 1999; 4:35-44.
42. Low-Beer S, Chan K, Wood E, Yip B, Montaner JS, O'Shaughnessy MV, et al. Health related quality of life among persons with HIV after the use of protease inhibitors. Qual Life Res 2000; 9:941-949.
43. Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS 2000; 14:181-187.
44. Nieuwkerk PT, Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MA. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001; 15:1985-1991.
45. Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, Francois C, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32:38-47.
46. Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS 2005; 19:395-405.
47. Jelsma J, Maclean E, Hughes J, Tinise X, Darder M. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care 2005; 17:579-588.
48. Burgoyne RW, Rourke SB, Behrens DM, Salit IE. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. AIDS Behav 2004; 8:151-163.
49. Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage 2001; 21:41-51.
50. Saunders DS, Burgoyne RW. Evaluating health-related well-being outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS 2002; 13:683-690.
51. Eriksson LE, Bratt GA, Sandstrom E, Nordstrom G. The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. Health Qual Life Outcomes 2005; 3:32.
52. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav 2003; 7:109-117.
53. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-493.
54. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998; 36:126-137.
55. Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA, et al. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res 2002; 11:273-282.
56. Wu AW, Rubin HR, Mathews WC, Ware JE Jr, Brysk LT, Hardy WD, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991; 29:786-798.
57. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995; 33:AS173-AS182.
58. Burgess A, Dayer M, Catalan J, Hawkins D, Cazzard B. The reliability and validity of two HIV-specific health-related Quality-of-Life measures: a preliminary analysis. AIDS 1993; 7:1001-1008.
59. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997; 6:531-554.
60. Lin MK, Wu AW, Revicki DA. Incorporating quality of life measures in HIV clinical trials. HIV Clin Trials 2002; 3:202-218.
61. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978; 1:373-378.
62. McCorkle R, Cooley M, Shea J. A User's Manual for the Symptom Distress Scale. Philadelphia: University of Pennsylvania; 1998.
63. Ragsdale D, Morrow JR. Quality of life as a function of HIV classification. Nurs Res 1990; 39:355-359.
64. Lovejoy NC, Morgenroth BN, Paul S, Freeman E, Christianson B. Potential predictors of information-seeking behavior by homosexual/bisexual (gay) men with a human immunodeficiency virus seropositive health status. Cancer Nurs 1992; 15:116-124.
65. Velikova G, Wright EP, Smith AB, Cull A, Gould A, Forman D, et al. Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. J Clin Oncol 1999; 17:998-1007.
66. Taenzer PA, Speca M, Atkinson MJ, Bultz BD, Page S, Harasym P, et al. Computerized quality-of-life screening in an oncology clinic. Cancer Pract 1997; 5:168-175.
67. Cronbach LJ. Coefficient alpha and the internal structure of test. Psychometricka 1951; 16:297-334.
68. Verbeke G, Mohlenberghs G. Linear Mixed Models in Practice: A SAS Oriented Approach. New York: Springer; 1997.
69. Wu AW. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS 2000; 14:1449-1451.